Attemz Caution For Usage

Incompatibilities: Aztreonam should not be physically mixed with any other drug, antibiotic or diluent, except those listed in the Dosage & Administration under Reconstitution for Intravenous infusion.
With intermittent infusion of aztreonam and another drug via a common delivery tube, the tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions. The drugs should not be delivered simultaneously.
Special precautions for disposal and other handling: Reconstitution: Aztreonam for injection 1 g vial are supplied in 15 mL vials.
Upon the addition of the diluent the contents should be shaken immediately and vigorously. Vials of reconstituted aztreonam are not intended for multi-dose use, and any unused solution from a single dose must be discarded. Depending on the type and amount of diluent, the pH ranges from 4.5 to 7.5, and the colour may vary from colourless to light straw-yellow, which may develop a slight pink tint on standing; however, this does not affect the potency.
For intramuscular injection: For 1 gram of aztreonam add at least 3 mL of sterile water for injections or 0.9% sodium chloride injection and shake well.
For intravenous injection: To the contents of the vial add 6 to 10 mL of sterile water for injections and shake well. Slowly inject directly into the vein over a period of 3 to 5 minutes.
For intravenous infusion: Vials: For each gram of aztreonam add at least 3 mL of sterile water for injections and shake well.
Dilute this initial solution with an appropriate infusion solution to a final concentration less than 2% w/v (at least 50 mL solution per gram of aztreonam). The infusion should be administered over 20-60 minutes.
Appropriate infusion solutions include: 0.9% Sodium Chloride Injection, 10% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Sodium Lactate Ringer Injection.
A volume control administration set may be used to deliver the initial solution of aztreonam into a compatible infusion solution being administered. With use of a Y-tube administration set, careful attention should be given to the calculated volume of aztreonam solution required so that the entire dose will be infused.
If aztreonam and metronidazole are to be used together, they should be administered separately as a cherry red colour has been observed after storage of solutions containing combinations of the two products.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.